Form 4 for CRL Charles River Laboratories
Accepted 2026-05-11 16:48:31 ET · period of report 2026-05-08 · accession 0001100682-26-000059 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-05-11 16:48 | 2026-05-08 | CRL | MACKAY MARTIN | Dir | A - Grant | $177.62 | +2,845 | 17.1K | +20% | +$505.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-08 | A | A | 1,438 | $177.62 | 15,730 | D | — | — | (F1) The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. |
| 2 | Common | Common Stock | 2026-05-08 | A | A | 1,407 | $177.62 | 17,137 | D | — | — | (F2) The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders. |